---
title: "Sanara MedTech Shareholders Reaffirm Board and Governance Policies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289241148.md"
description: "Sanara MedTech shareholders reaffirmed the existing board slate and governance policies at their June 4, 2026 annual meeting. Key outcomes included electing nine directors, ratifying Weaver and Tidwell as auditor, and approving a triennial schedule for executive compensation votes through 2029. While analysts maintain a 'Buy' rating with a $32 target, TipRanks' AI analyst rates the stock 'Neutral' due to improved operating performance offset by balance-sheet leverage risks."
datetime: "2026-06-09T21:35:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289241148.md)
  - [en](https://longbridge.com/en/news/289241148.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289241148.md)
generator: "portal-rs"
---

# Sanara MedTech Shareholders Reaffirm Board and Governance Policies

### Introducing TipRanks MCP for Agents

-   Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
-   Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Sanara MedTech ( (SMTI) ) just unveiled an update.

Sanara MedTech shareholders convened on June 4, 2026, for the company’s annual meeting, where 6,701,593 shares of common stock were represented in person or by proxy. Investors elected nine directors, including Seth D. Yon and Ronald T. Nixon, to one-year terms ending with the 2027 annual meeting, reaffirming the existing board slate and signaling continuity in corporate governance.

Shareholders also ratified the appointment of Weaver and Tidwell, L.L.P. as the independent auditor for fiscal 2026 and approved, on an advisory basis, the compensation of the company’s named executive officers. In a key governance decision, investors backed holding advisory votes on executive pay every three years, and the board adopted this triennial schedule through at least the 2029 annual meeting, shaping how often stakeholders formally weigh in on compensation policies.

The most recent analyst rating on (SMTI) stock is a Buy  
 with a $32.00 price target.  
 To see the full list of analyst forecasts on Sanara MedTech stock,  
 see the SMTI Stock Forecast page. 

**Spark’s Take on SMTI Stock**

According to Spark, TipRanks’ AI Analyst, SMTI is a Neutral.

The score is driven primarily by improving operating performance and a positive earnings update with reaffirmed growth guidance and better profitability trends, partially offset by significant balance-sheet leverage risk and a high valuation; technicals are moderately supportive but not strongly bullish given the stock remains below its 200-day average.

To see Spark’s full report on SMTI stock,  
 click here. 

**More about Sanara MedTech**

Sanara MedTech Inc. is a medical technology company that operates in the healthcare sector. The company focuses on developing and commercializing advanced medical products and services, with its shares actively held and voted on by a broad base of common stock shareholders.

**Average Trading Volume:** 54,219

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $202.4M

Find detailed analytics on SMTI stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [SMTI.US](https://longbridge.com/en/quote/SMTI.US.md)

## Related News & Research

- [Lake Street Reaffirms Their Hold Rating on Sanara MedTech (SMTI)](https://longbridge.com/en/news/297056244.md)
- [Mamdani is putting AI on recess for 600,000 students](https://longbridge.com/en/news/297813637.md)
- [TrustFinance Community Choice Awards 2026 Opens Global Voting](https://longbridge.com/en/news/297658492.md)
- [Vantiva announces combined shareholders meeting](https://longbridge.com/en/news/297806817.md)
- [Security Risk Advisors Launches SCALR AI as a Free SOC AI Platform for Security Teams](https://longbridge.com/en/news/297523531.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**